2. Academic Validation
  3. Inhibitory targeting cGAS-STING-TBK1 axis: Emerging strategies for autoimmune diseases therapy

Inhibitory targeting cGAS-STING-TBK1 axis: Emerging strategies for autoimmune diseases therapy

  • Front Immunol. 2022 Sep 12:13:954129. doi: 10.3389/fimmu.2022.954129.
Min Zhang 1 2,  Yan Zou 1 2,  Xujun Zhou 1 2,  Jinming Zhou 1 2
Affiliations

Affiliations

  • 1 Key Laboratory of the Ministry of Education for Advanced Catalysis Materials, Department of Chemistry, Zhejiang Normal University, Jinhua, China.
  • 2 Drug development and innovation center, College of Chemistry and Life Sciences, Zhejiang Normal University, Jinhua, China.
PMID: 36172373 DOI: 10.3389/fimmu.2022.954129
Abstract

The cGAS-STING signaling plays an integral role in the host immune response, and the abnormal activation of cGAS-STING is highly related to various autoimmune diseases. Therefore, targeting the cGAS-STING-TBK1 axis has become a promising strategy in therapy of autoimmune diseases. Herein, we summarized the key pathways mediated by the cGAS-STING-TBK1 axis and various cGAS-STING-TBK1 related autoimmune diseases, as well as the recent development of cGAS, STING, or TBK1 selective inhibitors and their potential application in therapy of cGAS-STING-TBK1 related autoimmune diseases. Overall, the review highlights that inhibiting cGAS-STING-TBK1 signaling is an attractive strategy for autoimmune disease therapy.

Keywords

CGAS; STING; TBK1; autoimmune disease; inhibitor.

Figures